Living With MS

Discussing all aspects of Multiple Sclerosis, various treatments, including accurate information regarding Tysabri.

Thursday, April 30, 2009

Hi everyone, for those of you looking for accurate Tysabri information...,

These are various reports/data which were released awhile ago at the AAN regarding the outcomes of Tysabri meeting and exceeding primary endpoints and the newest data released 61st annual AAN meeting which shows that Tysabri promotes remyelination, woo hoo!

As to efficacy in preventing further relapses, the percentages of the different ABCR drugs versus Tysabri (67%-29%) were as follows:

Tysabri was 67%, Avonex (Interferon beta-1a IM) 32%, Betaseron(R) (Interferon beta-1b) 34%, Copaxone(R) (glatiramer acetate) 29%, and Rebif(R) (Interferon beta-1a SC) 32%.

Data Show Tysabri Had Improvement in Quality of Life Assessments

Tysabri Impacts Measures of Visual Function

Tysabri Impacts Measures of Disability Progression

Data Demonstrates Tysabri Significantly Reduced Corticosteroid Use, Hospitalizations and Increases the Proportion of Disease-Free Patients

Tysabri Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years

Tysabri Significantly Reduces Vision Loss Tysabri

Demonstrates Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis

Tysabri Demonstrates Significant Improvement in Functional Outcomes

Tysabri Is the Only Marketed MS Treatment To Show Both Significant Slowing In Disability Progression and Sustained Improvement in Physical Disability

***28 April 2009** MRI Data Showing Tysabri Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology -- Additional data suggests improvement in Tysabri patients across clinical and patient-reported outcomes

*** ***

*** ***

*** ***

*** ***

Hope this information helps those of you looking for accurate Tysabri information..., enjoy the rest of your week everyone, I know I will!

Love, LaurenSmile


Post a Comment

Links to this post:

Create a Link

<< Home